Apostolova Liana G
Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):419-34. doi: 10.1212/CON.0000000000000307.
This article discusses the recent advances in the diagnosis and treatment of Alzheimer disease (AD).
In recent years, significant advances have been made in the fields of genetics, neuroimaging, clinical diagnosis, and staging of AD. One of the most important recent advances in AD is our ability to visualize amyloid pathology in the living human brain. The newly revised criteria for diagnosis of AD dementia embrace the use for biomarkers as supportive evidence for the underlying pathology. Guidelines for the responsible use of amyloid positron emission tomography (PET) have been developed, and the clinical and economic implications of amyloid PET imaging are actively being explored.
Our improved understanding of the clinical onset, progression, neuroimaging, pathologic features, genetics, and other risk factors for AD impacts the approaches to clinical diagnosis and future therapeutic interventions.
本文讨论了阿尔茨海默病（AD）诊断和治疗的最新进展。
近年来，AD在遗传学、神经影像学、临床诊断及分期等领域取得了重大进展。AD领域最近最重要的进展之一是我们能够在活体人脑中可视化淀粉样蛋白病理。新修订的AD痴呆诊断标准纳入了使用生物标志物作为潜在病理的支持证据。已制定了淀粉样蛋白正电子发射断层扫描（PET）的合理使用指南，并且正在积极探索淀粉样蛋白PET成像的临床和经济意义。
我们对AD临床发病、进展、神经影像学、病理特征、遗传学及其他危险因素的深入了解影响了临床诊断方法和未来的治疗干预措施。
